CN105209881B - 从细胞培养上清液和生物流体分离并纯化微泡的方法 - Google Patents

从细胞培养上清液和生物流体分离并纯化微泡的方法 Download PDF

Info

Publication number
CN105209881B
CN105209881B CN201480026884.6A CN201480026884A CN105209881B CN 105209881 B CN105209881 B CN 105209881B CN 201480026884 A CN201480026884 A CN 201480026884A CN 105209881 B CN105209881 B CN 105209881B
Authority
CN
China
Prior art keywords
microvesicles
microbubbles
cells
fluid
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480026884.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105209881A (zh
Inventor
E·V·巴迪亚瓦斯
A·Q·沙比尔
S·C·戴维斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Priority to CN202110013769.7A priority Critical patent/CN112795533A/zh
Publication of CN105209881A publication Critical patent/CN105209881A/zh
Application granted granted Critical
Publication of CN105209881B publication Critical patent/CN105209881B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/983—Blood, e.g. plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/86—Products or compounds obtained by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
CN201480026884.6A 2013-03-13 2014-03-12 从细胞培养上清液和生物流体分离并纯化微泡的方法 Active CN105209881B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110013769.7A CN112795533A (zh) 2013-03-13 2014-03-12 从细胞培养上清液和生物流体分离并纯化微泡的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361778591P 2013-03-13 2013-03-13
US61/778,591 2013-03-13
PCT/US2014/024629 WO2014159662A1 (en) 2013-03-13 2014-03-12 Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110013769.7A Division CN112795533A (zh) 2013-03-13 2014-03-12 从细胞培养上清液和生物流体分离并纯化微泡的方法

Publications (2)

Publication Number Publication Date
CN105209881A CN105209881A (zh) 2015-12-30
CN105209881B true CN105209881B (zh) 2021-01-22

Family

ID=51625222

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480026884.6A Active CN105209881B (zh) 2013-03-13 2014-03-12 从细胞培养上清液和生物流体分离并纯化微泡的方法
CN202110013769.7A Pending CN112795533A (zh) 2013-03-13 2014-03-12 从细胞培养上清液和生物流体分离并纯化微泡的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110013769.7A Pending CN112795533A (zh) 2013-03-13 2014-03-12 从细胞培养上清液和生物流体分离并纯化微泡的方法

Country Status (13)

Country Link
US (3) US10500231B2 (enExample)
EP (3) EP2972193B1 (enExample)
JP (3) JP6562897B2 (enExample)
CN (2) CN105209881B (enExample)
AU (4) AU2014244618A1 (enExample)
CA (1) CA2906502A1 (enExample)
DK (2) DK2972193T3 (enExample)
ES (2) ES2949637T3 (enExample)
FI (1) FI3677271T3 (enExample)
HU (2) HUE049003T2 (enExample)
PL (2) PL2972193T3 (enExample)
PT (2) PT2972193T (enExample)
WO (1) WO2014159662A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
HUE049003T2 (hu) 2013-03-13 2020-09-28 Univ Miami Eljárás mikrovezikulumok izolálására és tisztítására sejttenyészet-felülúszóból és biológiai folyadékból
US20180325830A1 (en) 2017-05-09 2018-11-15 Vivex Biomedical, Inc. Coated biological composition
US11160904B2 (en) 2017-05-09 2021-11-02 Vivex Biologies Group, Inc. Biological composition in a protectant shroud and methods
US9687511B2 (en) 2015-03-06 2017-06-27 Vivex Biomedical, Inc. Acellular biologic composition and method of manufacture
EP3267965A4 (en) * 2015-03-11 2018-11-14 Atta Behfar Exosome delivery technology
WO2016149358A1 (en) * 2015-03-16 2016-09-22 Duncan Ross Method of treatment comprising membrane-enclosed vesicle
WO2017023690A1 (en) * 2015-07-31 2017-02-09 Exoceuticals, Inc. Exosome compositions and methods for preparation and use thereof for regulating and conditioning skin and hair
KR102418785B1 (ko) 2015-09-25 2022-07-08 (주)프로스테믹스 식물 착즙물 유래 세포 외 소포체를 포함하는 피부 개선 및 탈모 방지용 조성물
KR102475127B1 (ko) * 2015-09-30 2022-12-07 (주)아모레퍼시픽 인삼 유래의 엑소좀 유사 베지클을 포함하는 탈모 방지 또는 육모 촉진용 조성물
EP3397264A4 (en) * 2015-12-30 2019-06-05 The Regents of The University of California METHOD FOR IMPROVED PREPARATION AND INSULATION OF CELL-DERIVED VESICLES
JP2019505590A (ja) * 2016-01-19 2019-02-28 ジェイ． サイレン、マッティ 癌の予防、処置および／または緩和における使用のための方法および組成物
KR102475129B1 (ko) * 2016-03-22 2022-12-07 (주)아모레퍼시픽 인삼 유래의 엑소좀 유사 베지클을 유효성분으로 포함하는 항노화용 조성물
WO2018039100A2 (en) * 2016-08-23 2018-03-01 Albert Einstein College Of Medicine, Inc. Stem cell-produced microvesicles for treating tendon pathologies
WO2018130554A1 (en) * 2017-01-11 2018-07-19 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Mesenchymal stem cell-derived extracellular vesicles and their medical use
JP2020528766A (ja) * 2017-07-26 2020-10-01 ロゼッタ エクソソーム 陽イオンを利用した細胞外小胞体の分離方法
ES2968625T3 (es) * 2017-07-27 2024-05-13 Univ Cornell Un método para la fijación y retención de vesículas extracelulares, vesículas extracelulares fijadas y un método para diagnosticar una enfermedad
AU2018335788B2 (en) * 2017-09-22 2024-08-15 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
US11471559B2 (en) 2017-11-20 2022-10-18 Vivex Biologics Group, Inc. Bioenergetic bone
CA3089825C (en) * 2018-01-29 2022-08-30 Forever Labs, Inc. System and method for isolating extracellular vesicles
CN108414334A (zh) * 2018-02-23 2018-08-17 中山大学附属第医院 一种从精液中分离提纯外泌体的方法
WO2020061550A1 (en) 2018-09-21 2020-03-26 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
CA3131922A1 (en) 2019-02-28 2020-09-03 William Samuel Fagg, Iv Amniotic fluid-derived extracellular vesicles and uses thereof for wound healing
IT201900024580A1 (it) * 2019-12-18 2021-06-18 Consiglio Nazionale Ricerche Vescicole extracellulari da microalghe
CN113384597A (zh) * 2020-03-13 2021-09-14 西比曼生物科技（上海）有限公司 含人体细胞衍生的细胞膜外囊泡的雾化吸入制剂、制法及其应用
CN111893093A (zh) * 2020-08-03 2020-11-06 沈阳三禾生物科技有限公司 一种脐带间充质干细胞来源的超微因子的制备方法
WO2022040516A1 (en) 2020-08-21 2022-02-24 University Of Miami Compositions and methods of treatment using microvesicles from bone marrow-derived mesenchymal stem cells
EP4230724A4 (en) * 2020-10-16 2024-05-22 FUJIFILM Corporation CULTURE MEDIUM FOR THE PRODUCTION OF EXTRACELLULAR VESICLES, CULTURE MEDIUM KIT, ADDITIVE AND METHOD FOR THE PRODUCTION OF EXTRACELLULAR VESICLES
CN114081900B (zh) * 2021-02-24 2024-11-22 济宁医学院附属医院 间充质干细胞来源的纳米微囊泡在制备治疗子痫前期的药物中的应用
CN115212230B (zh) * 2021-04-21 2024-12-27 时比曼生物科技(上海)有限公司 含有干细胞胞外囊泡的药物组合物及其在呼吸道炎症治疗中的应用
US20230390341A1 (en) 2022-04-19 2023-12-07 University Of Miami Methods and compositions for prevention and treatment of graft versus host disease
KR20240028586A (ko) * 2022-08-24 2024-03-05 (주) 테라베스트 인간 세포 유래 미세소포체 및 히알루론산 또는 콜라겐을 포함하는 조성물 및 이의 용도
CN116898781B (zh) * 2023-02-07 2025-08-15 中国中医科学院中医基础理论研究所 大麦苗外泌体在制备具有抗衰老修护作用的产品中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102007144A (zh) * 2006-12-29 2011-04-06 斯洛柏塔盖兹欧洲有限公司 衍生自重组酵母的具有止血活性的微泡及其用途
WO2012002760A2 (ko) * 2010-07-01 2012-01-05 포항공과대학교 산학협력단 세균유래 마이크로베시클을 이용한 암치료 및 암진단 방법
WO2012020307A2 (en) * 2010-08-13 2012-02-16 The University Court Of The University Of Glasgow Therapeutic uses of microvesicles and related micrornas
WO2013022786A2 (en) * 2011-08-05 2013-02-14 University Of Louisville Research Foundation, Inc. Microrna biomarkers

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206861D0 (en) 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
AU6632496A (en) 1995-08-03 1997-03-05 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
ZA9811898B (en) 1997-12-29 2000-06-28 Ortho Mcneil Pharm Inc Anti-Inflammatory Compounds.
MY132496A (en) 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
US6413556B1 (en) 1999-01-08 2002-07-02 Sky High, Llc Aqueous anti-apoptotic compositions
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
GB9927320D0 (en) 1999-11-18 2000-01-12 Chiron Spa Exosome separation
EP2404603A1 (en) 2000-10-23 2012-01-11 Glaxosmithkline LLC Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases
EP1395652A2 (en) * 2000-11-30 2004-03-10 Stemron, Inc. Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same
GB0117583D0 (en) 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
KR100519384B1 (ko) 2002-08-13 2005-10-06 (주)누백스 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US8021847B2 (en) 2004-06-02 2011-09-20 Proxy Life Science Holdings, Inc. Microvesicle-based compositions and methods
WO2005121369A2 (en) * 2004-06-02 2005-12-22 Sourcepharm, Inc. Rna-containing microvesicles and methods therefor
KR20070058441A (ko) 2004-07-01 2007-06-08 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 면역억제성 엑소솜
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
US8637005B2 (en) 2005-11-07 2014-01-28 Amorcyte, Inc. Compositions and methods of vascular injury repair
WO2007103572A2 (en) 2006-03-09 2007-09-13 Aethlon Medical, Inc. Extracorporeal removal of microvesicular particles
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
EP2455492B1 (en) 2006-07-13 2013-11-20 The Ohio State University Research Foundation Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases
JP2010520874A (ja) 2007-03-09 2010-06-17 メルク・シャープ・エンド・ドーム・コーポレイション パピローマウイルスワクチン組成物
AU2008266014B2 (en) 2007-06-15 2013-06-06 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting drosha-mediated microRNA processing
EP2613149B1 (en) 2007-07-25 2014-09-17 University Of Louisville Research Foundation, Inc. Exosome-associated microRNA as a diagnostic marker
US20100255514A1 (en) * 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
US20100233216A1 (en) * 2007-10-15 2010-09-16 Vincenzo Cantaluppi Use of microvesicles (mvs) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularly in the treatment of diabetes by pancreatic islet transplantation, and related method
JP5261494B2 (ja) * 2007-10-29 2013-08-14 フレゼニウス メディカル ケア ドイッチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング 損傷しまたは傷害を受けた組織または臓器の内皮／上皮再生用医薬の製造のための、幹細胞由来微小胞（ｍｖ）の使用ならびにインビトロおよびインビボでの関連した方法
NZ586497A (en) 2008-01-04 2012-07-27 Lydac Neuroscience Ltd Microvesicles
US20120058492A1 (en) 2008-01-25 2012-03-08 Hansabiomed Ou Method and a Kit To Detect Malignant Tumors and Provide a Prognosis
US8617806B2 (en) 2008-01-25 2013-12-31 Hansabiomed Ou Method to measure and characterize microvesicles in the human body fluids
ES2936256T3 (es) * 2008-02-01 2023-03-15 Massachusetts Gen Hospital Uso de microvesículas en el diagnóstico, y pronóstico de enfermedades y afecciones médicas
PL2254586T3 (pl) 2008-02-22 2015-09-30 Agency For Science Tech And Research Astarstar Cząstki mezenchymalnych komórek macierzystych
FR2928926B1 (fr) 2008-03-18 2015-08-21 Centre Nat Rech Scient Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes
CA2720048A1 (en) * 2008-04-16 2009-10-22 Biogen Idec Ma Inc. Method of isolating biomacromolecules using polyalkylene glycol and transition metals
US10545149B2 (en) 2008-10-06 2020-01-28 Morehouse School Of Medicine Detection of HIV-related proteins in urine
EP2350274B1 (en) 2008-10-21 2019-01-23 The General Hospital Corporation Cell transplantation
BRPI0921043A2 (pt) 2008-11-12 2018-08-07 Caris Life Sciences Luxembourg Holdings métodos e sistemas para usar exossomas para determinar fenótipos
JP5746051B2 (ja) 2009-01-15 2015-07-08 ラボラトリー コーポレイション オブ アメリカ ホールディングス Ｈｅｒ−３の測定による患者の反応を判定する方法
ES2683352T3 (es) 2009-04-13 2018-09-26 Inserm - Institut National De La Santé Et De La Recherche Médicale Partículas de HPV y usos de las mismas
EP2419144B1 (en) 2009-04-17 2019-08-07 Oxford University Innovation Limited Composition for delivery of genetic material
BRPI0900815A2 (pt) 2009-04-23 2010-12-28 Sociedade Benef Israelita Bras Hospital Albert Einstein método para isolamento de exossomos a partir de soluções biológicas utilizando nanopartìculas de óxido de ferro
KR20120081972A (ko) 2009-07-02 2012-07-20 아이티에이치 임뮨 세라피 홀딩스 에이비 엑소좀에 기초한 암의 치료
BR112012001077A2 (pt) * 2009-07-16 2020-08-11 The General Hospital Corporation extração de ácido nucleico, métodos para avaliar a qualidade de uma extração de ácido nucleico e de uma amostra biológica, para ober ácido nucleico a partir de uma amostra biológica, para analisar rna de microvesículas e para diagnosticar e monitorar um indivíduo, e, kit
CN102812362B (zh) 2010-01-08 2015-02-11 卡瓦迪斯有限责任公司 用于预测心血管事件的外来体生物标志物的确定
WO2011097480A1 (en) 2010-02-05 2011-08-11 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
US20120053976A1 (en) 2010-08-31 2012-03-01 Xerox Corporation System and method for determining whether service costs can be reduced
US20120093885A1 (en) * 2010-10-18 2012-04-19 Northwestern University Therapeutic vesicles
JP5911874B2 (ja) 2010-10-18 2016-04-27 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 発毛を促進又は増強するためのエキソソームの使用
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
WO2012126531A1 (en) 2011-03-24 2012-09-27 Cavadis B.V. Method for diagnosing acute coronary syndrome (acs)
WO2012110253A2 (en) 2011-02-18 2012-08-23 Cavadis B.V. Exosomal biomarkers for cardiovascular events
WO2012110099A1 (en) 2011-02-18 2012-08-23 Cavadis B.V. Determination of exosomal biomarkers for predicting cardiovascular events
WO2012135844A2 (en) 2011-04-01 2012-10-04 Cornell University Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers
CN103717284B (zh) 2011-06-08 2016-02-24 新加坡科技研究局 通过约束共水合色谱纯化生物制品
EP2734543B1 (en) 2011-07-24 2018-10-03 Carmel-Haifa University Economic Corp. Lactoferrin fragments and use thereof
ITRM20110403A1 (it) 2011-07-28 2013-01-29 Ospedale Pediatrico Bambino Gesu Microvescicole isolate da cellule mesenchimali come agenti immunosoppressori.
EP2604288A1 (en) 2011-12-16 2013-06-19 Biocant - Associação De Transferência De Tecnologia Nanoparticles and uses thereof
US20150052361A1 (en) 2011-12-23 2015-02-19 Appbyyou Gmbh Method for setting up an encrypted connection between two communication appliances following prior key interchange via a shorthaul connection
US20130273544A1 (en) 2012-04-17 2013-10-17 Life Technologies Corporation Methods and compositions for exosome isolation
US9005888B2 (en) 2012-06-14 2015-04-14 System Biosciences, Llc Methods for microvesicle isolation and selective removal
WO2013188832A1 (en) * 2012-06-14 2013-12-19 System Biosciences, Llc Methods for microvesicle isolation and selective removal
EP2687219A1 (en) * 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
EP2882445B1 (en) 2012-08-13 2019-04-24 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
WO2014076137A1 (en) 2012-11-13 2014-05-22 Lötvall Jan Delivery of therapeutic agent
HUE049003T2 (hu) 2013-03-13 2020-09-28 Univ Miami Eljárás mikrovezikulumok izolálására és tisztítására sejttenyészet-felülúszóból és biológiai folyadékból
US20180104186A1 (en) 2013-03-13 2018-04-19 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
WO2015038075A1 (en) 2013-09-16 2015-03-19 Agency For Science, Technology And Research Method
WO2016043654A1 (en) 2014-09-15 2016-03-24 Agency For Science, Technology And Research Methods of treating graft versus host disease (gvhd) or epidermolysis bullosa (eb) with exosomes
US20170173113A1 (en) 2014-03-13 2017-06-22 Research Institute At Nationwide Children's Hospital Methods of delivering heparin binding epidermal growth factor using stem cell generated exosomes
WO2016172598A1 (en) 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes and uses thereof
BR112017025562A2 (pt) 2015-05-29 2018-08-07 Merck Sharp & Dohme Corp. métodos para tratar câncer em um indivíduo e para tratar um indivíduo humano diagnosticado com câncer
KR20170085010A (ko) 2016-01-12 2017-07-21 주식회사 강스템바이오텍 고함량의 성장인자를 함유한 줄기세포 유래 엑소좀
US11918687B2 (en) 2016-01-15 2024-03-05 Orbsen Therapeutics Limited SDC-2 exosome compositions and methods of isolation and use
AU2018335788B2 (en) 2017-09-22 2024-08-15 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
WO2022040516A1 (en) 2020-08-21 2022-02-24 University Of Miami Compositions and methods of treatment using microvesicles from bone marrow-derived mesenchymal stem cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102007144A (zh) * 2006-12-29 2011-04-06 斯洛柏塔盖兹欧洲有限公司 衍生自重组酵母的具有止血活性的微泡及其用途
WO2012002760A2 (ko) * 2010-07-01 2012-01-05 포항공과대학교 산학협력단 세균유래 마이크로베시클을 이용한 암치료 및 암진단 방법
WO2012020307A2 (en) * 2010-08-13 2012-02-16 The University Court Of The University Of Glasgow Therapeutic uses of microvesicles and related micrornas
WO2013022786A2 (en) * 2011-08-05 2013-02-14 University Of Louisville Research Foundation, Inc. Microrna biomarkers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Functional Characterization of Extracellular Vesicles Produced by Bacteroides gingivalis;Daniel Grenier, et al;《Infection and Immunity》;19870131;第55卷(第1期);第111页摘要，右栏第1-4段 *

Also Published As

Publication number Publication date
US20160184363A1 (en) 2016-06-30
FI3677271T3 (fi) 2023-06-06
US20200163999A1 (en) 2020-05-28
WO2014159662A1 (en) 2014-10-02
CN112795533A (zh) 2021-05-14
AU2018211351A1 (en) 2018-08-23
HUE062348T2 (hu) 2023-10-28
EP2972193A4 (en) 2016-09-07
CN105209881A (zh) 2015-12-30
JP7405389B2 (ja) 2023-12-26
AU2018211351C1 (en) 2020-12-10
JP6562897B2 (ja) 2019-08-21
PL2972193T3 (pl) 2020-08-24
PT3677271T (pt) 2023-05-31
AU2022206811B2 (en) 2024-08-15
US10500231B2 (en) 2019-12-10
EP3677271B1 (en) 2023-04-19
CA2906502A1 (en) 2014-10-02
ES2949637T3 (es) 2023-10-02
AU2018211351B2 (en) 2020-05-28
AU2020223723A1 (en) 2020-09-10
EP4218774A1 (en) 2023-08-02
US20230364150A1 (en) 2023-11-16
JP2016518109A (ja) 2016-06-23
JP2019195331A (ja) 2019-11-14
US11730768B2 (en) 2023-08-22
EP2972193B1 (en) 2019-12-18
PL3677271T3 (pl) 2023-08-21
HUE049003T2 (hu) 2020-09-28
AU2022206811A1 (en) 2022-08-18
JP2022084634A (ja) 2022-06-07
PT2972193T (pt) 2020-04-23
DK3677271T3 (da) 2023-05-22
EP2972193A1 (en) 2016-01-20
DK2972193T3 (da) 2020-03-23
US12453745B2 (en) 2025-10-28
AU2014244618A1 (en) 2015-10-08
EP3677271A1 (en) 2020-07-08
ES2778098T3 (es) 2020-08-07
JP7417301B2 (ja) 2024-01-18

Similar Documents

Publication Publication Date Title
JP7417301B2 (ja) 細胞培養上清および生体液からの微小胞の単離および精製のための方法
KR102722950B1 (ko) 수포성 표피박리증의 치료를 위한 방법 및 조성물
IL236213A (en) Pharmaceutical preparation to encourage the absorption of hematopoietic stem cells
US20180104186A1 (en) Methods and compositions for the treatment of epidermolysis bullosa
Öztürk et al. Immune regulation is more effective in the U937 inflammation model with mesenchymal stem cell extracellular vesicles stimulated by pro-inflammatory cytokines
HK40088378A (en) Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
HK40032447A (en) Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
HK40032447B (en) Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
HUMAN " FEDERICO II
EA047075B1 (ru) Способы и композиции для лечения буллезного эпидермолиза

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant